Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
Recommended
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
Shlomit Amar-Farkash, PhD, MSc, Anthem Innovation Israel, Tel Aviv, Israel compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with metastatic triple-negative breast cancer in the United States.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->